Trial Profile
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs Ecopipam (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Emalex Biosciences; Psyadon Pharmaceuticals
- 22 Sep 2021 Status changed from active, no longer recruiting to completed, according to Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 22 Sep 2021 Results (n=26) of an OLE assessing long-term safety and efficacy of ecopipam in treatment of children and adolescents with Tourette syndrome presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.